Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
A Phase II trial of 75 mCi/m2 131I-anti-TAG-72 high-affinity antibody CC49 was studied in 15 patients with hormone-resistant metastatic prostate cancer.


METHODS
Patients had adequate renal, liver and hematopoietic function. No previous cytotoxic chemotherapy was allowed and previous radiation was limited to 20% of the active bone marrow.


RESULTS
No acute adverse reactions occurred, but all patients had evidence of an immune response to CC49 by 4 wk. Six of 10 symptomatic patients had bone pain relief, but no patients met the radiographic or PSA criteria for objective response. Positive imaging of bone and/or soft-tissue lesions was noted for 13 of the 15 patients.


CONCLUSIONS
CC49 had a high frequency of tumor localization with evidence of anti-tumor effects (pain relief).
Meredith
R F
RF
Department of Radiation Oncology, University of Alabama at Birmingham 35294-3300.
Bueschen
A J
AJ
Khazaeli
M B
MB
Plott
W E
WE
Grizzle
W E
WE
Wheeler
R H
RH
Schlom
J
J
Russell
C D
CD
Liu
T
T
LoBuglio
A F
AF
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology*; D016499:Radioimmunotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D015899:Tomography, Emission-Computed, Single-Photon